NICE has recommended broadening NHS use of Novartis' IL-17 inhibitor Cosentyx to include children aged six to 17 with severe plaque psoriasis. The cost-effectiveness agency says in draft guidance that ...
Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the ...
Data showed that treatment with Cosentyx 300 mg in a 2 mL autoinjector (UnoReady pen) resulted in high efficacy and convenient administration. The data were presented at the European Academy of ...
Basel, May 20, 2022 — Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx ® ...
Approvals based on data from the JUNIPERA trial, showing that Cosentyx ® (secukinumab) reduced the risk of flare and disease activity compared to placebo over 2 years in pediatric patients 1 with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback